CN105939728A - 用于治疗和预防肾病和脂肪肝病的方法 - Google Patents

用于治疗和预防肾病和脂肪肝病的方法 Download PDF

Info

Publication number
CN105939728A
CN105939728A CN201580006608.8A CN201580006608A CN105939728A CN 105939728 A CN105939728 A CN 105939728A CN 201580006608 A CN201580006608 A CN 201580006608A CN 105939728 A CN105939728 A CN 105939728A
Authority
CN
China
Prior art keywords
diabetes
fatty liver
nonalcoholic
disease
canagliflozin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580006608.8A
Other languages
English (en)
Chinese (zh)
Inventor
K.S.尤斯金
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52544570&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105939728(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Priority to CN202110463410.XA priority Critical patent/CN113082021A/zh
Priority to CN202110463431.1A priority patent/CN113144204A/zh
Publication of CN105939728A publication Critical patent/CN105939728A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201580006608.8A 2014-01-31 2015-01-30 用于治疗和预防肾病和脂肪肝病的方法 Pending CN105939728A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202110463410.XA CN113082021A (zh) 2014-01-31 2015-01-30 用于治疗和预防肾病和脂肪肝病的方法
CN202110463431.1A CN113144204A (zh) 2014-01-31 2015-01-30 用于治疗和预防肾病和脂肪肝病的方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461934003P 2014-01-31 2014-01-31
US61/934003 2014-01-31
US201461948882P 2014-03-06 2014-03-06
US61/948882 2014-03-06
PCT/US2015/013644 WO2015116880A1 (en) 2014-01-31 2015-01-30 Methods for the treatment and prevention of renal disorders and fatty liver disorders

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202110463410.XA Division CN113082021A (zh) 2014-01-31 2015-01-30 用于治疗和预防肾病和脂肪肝病的方法
CN202110463431.1A Division CN113144204A (zh) 2014-01-31 2015-01-30 用于治疗和预防肾病和脂肪肝病的方法

Publications (1)

Publication Number Publication Date
CN105939728A true CN105939728A (zh) 2016-09-14

Family

ID=52544570

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201580006608.8A Pending CN105939728A (zh) 2014-01-31 2015-01-30 用于治疗和预防肾病和脂肪肝病的方法
CN202110463431.1A Pending CN113144204A (zh) 2014-01-31 2015-01-30 用于治疗和预防肾病和脂肪肝病的方法
CN202110463410.XA Pending CN113082021A (zh) 2014-01-31 2015-01-30 用于治疗和预防肾病和脂肪肝病的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202110463431.1A Pending CN113144204A (zh) 2014-01-31 2015-01-30 用于治疗和预防肾病和脂肪肝病的方法
CN202110463410.XA Pending CN113082021A (zh) 2014-01-31 2015-01-30 用于治疗和预防肾病和脂肪肝病的方法

Country Status (11)

Country Link
US (3) US20160339047A1 (cg-RX-API-DMAC7.html)
EP (1) EP3099328A1 (cg-RX-API-DMAC7.html)
JP (2) JP2017504649A (cg-RX-API-DMAC7.html)
KR (1) KR20160107344A (cg-RX-API-DMAC7.html)
CN (3) CN105939728A (cg-RX-API-DMAC7.html)
AU (2) AU2015210898A1 (cg-RX-API-DMAC7.html)
CA (1) CA2938406A1 (cg-RX-API-DMAC7.html)
EA (1) EA201691555A1 (cg-RX-API-DMAC7.html)
IL (1) IL246779A0 (cg-RX-API-DMAC7.html)
MX (1) MX2016010011A (cg-RX-API-DMAC7.html)
WO (1) WO2015116880A1 (cg-RX-API-DMAC7.html)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109806397A (zh) * 2017-11-20 2019-05-28 江苏恒瑞医药股份有限公司 Sglt2抑制剂与arb联合在制备治疗高血压等疾病的药物中的用途
CN110051851A (zh) * 2019-05-31 2019-07-26 江苏苏中药业集团股份有限公司 一种钠-葡萄糖共转运蛋白-2抑制剂与黄蜀葵花提取物的组合
CN113613659A (zh) * 2019-03-26 2021-11-05 詹森药业有限公司 用于治疗患有慢性肾病的糖尿病患者的卡格列净
WO2022104621A1 (zh) * 2020-11-19 2022-05-27 北京睿创康泰医药研究院有限公司 固定剂量的sglt-2抑制剂与血管紧张素转化酶抑制剂的组合物及用途
CN116390721A (zh) * 2020-10-30 2023-07-04 雷斯韦洛吉克斯公司 用于用bet溴结构域抑制剂和钠依赖性葡萄糖转运2抑制剂的组合改善肾功能的方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2018113437A (ru) * 2015-09-16 2019-10-17 Тобира Терапьютикс, Инк. Комбинированная терапия с использованием ценикривирока для лечения фиброза
CN108289963B (zh) * 2015-11-06 2023-08-29 营养Dna控股有限公司 用于测试对于口服葡萄糖负荷响应的方法和产品
GB201614455D0 (en) * 2016-08-24 2016-10-05 Univ Oxford Innovation Ltd Biomarkers
TWI835735B (zh) * 2017-06-12 2024-03-21 比利時商健生藥品公司 減少或預防第ii型糖尿病患者中心血管事件之方法
LT3716979T (lt) 2017-11-30 2025-07-10 Idorsia Pharmaceuticals Ltd 4-pirimidinsulfamido darinio derinys su sglt-2 inhibitoriumi, skirtas su endotelinu susijusių ligų gydymui
WO2022036506A1 (zh) * 2020-08-17 2022-02-24 天津睿创康泰生物技术有限公司 Sglt-2抑制剂与血管紧张素受体阻滞剂的组合物及用途
JP2024094532A (ja) 2022-12-28 2024-07-10 キヤノン株式会社 撮像設定装置および撮像装置
KR20240126452A (ko) * 2023-02-10 2024-08-21 가천대학교 산학협력단 칸데사르탄 또는 아질사르탄을 포함하는 조성물의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1181019A (zh) * 1995-04-07 1998-05-06 诺瓦蒂斯有限公司 含有贝那普利或贝那普利拉和维沙坦的药物组合物
WO2008113095A1 (en) * 2007-03-20 2008-09-25 Fibrotech Therapeutics Pty Ltd Compositions and therapies comprising tranilast compounds and angiotensin-converting enzyme (ace) inhibitors and/or angiotensin receptor blockers (arb)
WO2011120923A1 (en) * 2010-03-30 2011-10-06 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104109155A (zh) 2003-08-01 2014-10-22 田边三菱制药株式会社 新颖化合物
UY30730A1 (es) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
UY32030A (es) * 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916476A2 (pt) * 2008-12-01 2016-02-16 Invasc Therapeutics Inc composição, método de tratamento para um distúrbio relacionado ao sistema renina-angiotensina-aldosterona, método para reduzir a resistência à insulina, método para tratar um distúrbio relacionado à síndrome metabólica
CN102421433B (zh) * 2009-03-26 2015-09-23 阿贾伊·古普塔 用于治疗肾病的组合物和方法
MX366925B (es) * 2010-11-04 2019-07-31 Albireo Ab Inhibidores de ibat para el tratamiento de enfermedades hepaticas.
BR112013009531A2 (pt) * 2010-11-11 2016-07-19 Redx Pharma Ltd derivados de fármaco
US9034883B2 (en) * 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1181019A (zh) * 1995-04-07 1998-05-06 诺瓦蒂斯有限公司 含有贝那普利或贝那普利拉和维沙坦的药物组合物
WO2008113095A1 (en) * 2007-03-20 2008-09-25 Fibrotech Therapeutics Pty Ltd Compositions and therapies comprising tranilast compounds and angiotensin-converting enzyme (ace) inhibitors and/or angiotensin receptor blockers (arb)
WO2011120923A1 (en) * 2010-03-30 2011-10-06 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HIDDO J.等: "The Kidney in Type 2 Diabetes Therapy", 《THE REVIEW OF DIABETIC STUDIES》 *
JACQUELINE COELLN-HOUGHD: "Canagliflozin Advisory Committee Meeting", 《CANAGLIFLOZIN ADVISORY COMMITTEE MEETING》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109806397A (zh) * 2017-11-20 2019-05-28 江苏恒瑞医药股份有限公司 Sglt2抑制剂与arb联合在制备治疗高血压等疾病的药物中的用途
CN113613659A (zh) * 2019-03-26 2021-11-05 詹森药业有限公司 用于治疗患有慢性肾病的糖尿病患者的卡格列净
CN110051851A (zh) * 2019-05-31 2019-07-26 江苏苏中药业集团股份有限公司 一种钠-葡萄糖共转运蛋白-2抑制剂与黄蜀葵花提取物的组合
CN116390721A (zh) * 2020-10-30 2023-07-04 雷斯韦洛吉克斯公司 用于用bet溴结构域抑制剂和钠依赖性葡萄糖转运2抑制剂的组合改善肾功能的方法
WO2022104621A1 (zh) * 2020-11-19 2022-05-27 北京睿创康泰医药研究院有限公司 固定剂量的sglt-2抑制剂与血管紧张素转化酶抑制剂的组合物及用途
CN116234545A (zh) * 2020-11-19 2023-06-06 北京睿创康泰医药研究院有限公司 固定剂量的sglt-2抑制剂与血管紧张素转化酶抑制剂的组合物及用途

Also Published As

Publication number Publication date
EA201691555A1 (ru) 2017-01-30
AU2015210898A1 (en) 2016-07-28
US20160339047A1 (en) 2016-11-24
EP3099328A1 (en) 2016-12-07
JP2017504649A (ja) 2017-02-09
WO2015116880A1 (en) 2015-08-06
CN113144204A (zh) 2021-07-23
KR20160107344A (ko) 2016-09-13
CA2938406A1 (en) 2015-08-06
MX2016010011A (es) 2016-10-07
JP2020090511A (ja) 2020-06-11
US20180344756A1 (en) 2018-12-06
IL246779A0 (en) 2016-08-31
US20210121492A1 (en) 2021-04-29
AU2020281039A1 (en) 2021-01-07
CN113082021A (zh) 2021-07-09

Similar Documents

Publication Publication Date Title
US20210121492A1 (en) Methods for the treatment and prevention of renal disorders and fatty liver disorders
JP7454531B2 (ja) エンパグリフロジンを含む医薬組成物及びその使用
US12263153B2 (en) Pharmaceutical composition, methods for treating and uses thereof
JP6431959B2 (ja) エンパグリフロジンの治療的使用
JP6325084B2 (ja) エンパグリフロジンの治療的使用
JP6177992B2 (ja) エンパグリフロジンの治療的使用
JP2018131448A (ja) エンパグリフロジンの治療的使用
HK1215378A1 (zh) 药物组合物、治疗方法及其用途
HK40056944A (en) Methods for the treatment and prevention of renal disorders and fatty liver disorders
HK40055858A (en) Methods for the treatment and prevention of renal disorders and fatty liver disorders
HK1224940A1 (en) Methods for the treatment and prevention of renal disorders and fatty liver disorders
CN110740735A (zh) 用于减少或预防患有ii型糖尿病的患者中的心血管事件的方法
EA042969B1 (ru) Фармацевтическая композиция, содержащая эмпаглифлозин, и ее применения

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1224940

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160914

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1224940

Country of ref document: HK